Answers are grounded in this paper and cite their sources.
Observational study evaluates clinical remission in IBD patients receiving subcutaneous infliximab, indicating promising effectiveness and safety.
Background Infliximab (IFX) is an approved biological therapy for Crohn’s disease (CD) and ulcerative colitis (UC). The subcutaneous (SC) formulation of IFX (CT-P13) has shown comparable efficacy to intravebous (IV) IFX, with higher IFX through levels and reduced immunogenicity. This study aimed to evaluate the clinical effectiveness and safety of SC IFX (CT-P13) in a real-world cohort of patients with inflammatory bowel disease (IBD). Methods A retrospective, single-centre, observational study was conducted including adult patients with IBD receiving SC IFX (CT-P13). The primary endpoint was the rate of clinical remission at week 14, and at the end of follow-up. Clinical remission was defined as a Harvey–Bradshaw Index (HBI) ≤ 4 for CD, and a partial Mayo Score (pMS) ≤ 2 for UC or unclassified colitis (IBD-U). Secondary outcomes included changes in faecal calprotectin (FC), serum IFX trough levels, presence of anti-drug antibodies (ADA), and treatment-related adverse events (AEs). Results Baseline characteristics are presented in Table 1. Clinical remission rate, in CD patients, increased from 58.3% at baseline to 91.3% at week 14 (p = 0.0156), and 75.0% at the end of follow-up (p = 0.2891; median 26.6 weeks [IQR 15.6–43.9]). HBI significantly decreased through follow up Figure1A. No significant changes were observed in clinical remission or pMS among patients with UC or IBD-U. Median FC levels (µg/g) decreased from 684 (113.6–2335) at baseline to 583 (135–1855) at week 14, and further to 288.5 (128–1531.3) at the end of follow-up (median 21.4 weeks [IQR 13–41]), although differences were not statistically significant (p > 0.05; Figure 1B). Median serum IFX trough levels (µg/mL) increased significantly from 5.5 (3.2–8.9) at baseline to 18.6 (10.5–38.2) at week 14 (p = 0.0042), and to 18.9 (8.8–31.7) at the end of follow-up (p = 0.0025; Figure 1C). Anti-IFX antibodies were detected in 4 patients (14.3%), one of whom had pre-existing antibodies prior to switching. AEs occurred in 6 patients (21.4%), including 1 case of drug-induced liver injury resembling autoimmune hepatitis, 3 cutaneous reactions, 1 case of arthralgia, and 1 of headache. SC IFX was discontinued in 8 patients (28.6%): 5 due to AEs, 2 due to persistent disease activity with low IFX levels, and 1 due to ongoing clinical activity despite adequate drug levels. Conclusion Subcutaneous IFX (CT-P13) appears to be an effective and well-tolerated therapeutic option for patients with Crohn’s disease in clinical practice. The observed increase in serum IFX concentrations is consistent with previous publications. References: 1. Schreiber S, Ben-Horin S, Leszczyszyn J, et al. Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease. Gastroenterology. 2021;160(7):2340-2353. doi:10.1053/j.gastro.2021.02.068. 2. Buisson A, Nachury M, Reymond M, et al. Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases: the REMSWITCH study. Clin Gastroenterol Hepatol. 2023;21(9):2338-2346.e3. doi:10.1016/j.cgh.2022.08.011 3. Smith PJ, Critchley L, Storey D, et al. Efficacy and safety of elective switching from intravenous to subcutaneous infliximab (CT-P13): a multicentre cohort study. J Crohns Colitis. 2022;16(9):1436-1446. doi:10.1093/ecco-jcc/jjac053 4. Smith PJ, Fumery M, Leong RW, Novak K, Dignass A. Real-world experience with subcutaneous infliximab: broadening treatment strategies for inflammatory bowel disease. Expert Rev Clin Immunol. 2023;19(9):1143-1156. doi:10.1080/1744666X.2023.2231148 Conflict of interest: Cárdenas Patiño, Jenny Victoria: No conflict of interest Mr. Moralejo Lozano, Óscar: I have received educational funding from Abbvie, Johnson & Johnson, Takeda, Kern Pharma, Alfasigma, Pfizer, Lilly, Sandoz, Dr. Falk Pharma, Ferring, and Tillotts. I have also served as a speaker for Abbvie, Takeda, Alfasigma, and Lilly. Abanades Tercero, María: No conflict of interest Carrillo Ramos, Maria Jesus: María Jesús Carrillo Ramos has served as a speaker for Takeda and Alfasigma. Gigante González De La Aleja, Gema: No conflicts Ruano Díaz, Lucía: No conflict of interest Salmoral Luque, Rosario: Alfasigma, Janssen Gómez Rodriguez, Rafael Ángel: No conflict of interest
No takes yet. Share an insight, caveat, or question.
Patiño et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: